ECDC and EMA have issued a joint statement on adapted COVID-19 vaccines and considerations for their use during the upcoming autumn 2023 vaccination campaigns.
Currently authorised vaccines continue to be effective at preventing hospitalisation, severe disease and death due to COVID-19. However, protection against the virus declines over time as new SARS-CoV-2 variants emerge.
Entire content available on: https://www.ecdc.europa.eu/en/news-events/ecdc-ema-statement-updating-covid-19-vaccines-composition-new-sars-cov-2-virus-variants
Language
English French Spanish Portuguese Russian ItalianTypology
StatementsTopic
Covid-19 Prevention Vaccine Infectious DiseasesTarget
Public Health Primary careCountries
Europe & UK